连续性肾脏替代治疗联合血液灌流在横纹肌溶解合并急性肾损伤中的研究进展  

Research progresses in blood perfusion joint continuous renal replacement therapy in rhabdomyolysisinduced acute kidney injury

作　　者：周晓春 杨莹莹[1] 付平[1] ZHOU Xiao-chun;YANG Ying-ying;FU Ping(Department of Nephrology,Kidney Research Institute,West China Hospital of Sichuan University,Chengdu 610041,China;Department of Nephrology,Guanghan Hospital of Traditional Chinese Medicine,Deyang 618300,China)

机构地区：[1]四川大学华西医院肾脏内科/四川大学华西肾脏病研究所,成都610041 [2]广汉市中医医院肾脏内科,德阳618300

出　　处：《中国血液净化》2024年第7期534-537,共4页Chinese Journal of Blood Purification

摘　　要：横纹肌溶解(rhabdomyolysis,RM)是一种多因素造成的骨骼肌损伤及其分解产物释放入血液循环中的临床综合征。急性肾损伤(acute kidney injury,AKI)是横纹肌溶解的常见并发症,主要与肌红蛋白堵塞肾小管及其直接肾毒性作用有关。RM合并AKI的治愈率较低、死亡率较高。既往有研究显示连续性肾脏替代治疗(continuous renal replacement therapy,CRRT)联合血液灌流(hemoperfusion,HP)可以有效治疗RM合并AKI,本文就CRRT联合HP治疗RM合并AKI进行了综述,旨在为临床治疗决策及后续研究提供参考。Rhabdomyolysis(RM)is a multifactorial clinical syndrome of skeletal muscle injury and release of its breakdown products into the circulation.Acute kidney injury(AKI)is a common complication of RM,which is mainly related to myoglobin occlusion of renal tubules and its direct nephrotoxic effects,and others.RM-induced AKI has a low cure rate and high mortality.Previous studies have shown that continuous renal replacement therapy(CRRT)combined with hemoperfusion(HP)can be effective in treating RM-induced AKI.This article provides a review of CRRT combined with HP in the treatment of RM-induced AKI with the aim to provide a reference for clinical therapeutic decision-making and possible follow-up studies.

关 键 词：横纹肌溶解 急性肾损伤 肌红蛋白 连续性肾脏替代治疗 血液灌流 

分 类 号：R459.5[医药卫生—治疗学]